Merlin Biotech, Inc.
Monday, February 26, 2024
MERLIN Biotech is a pre-clinical stage mRNA platform company with a novel 1st in class cancer immunotherapy with exclusive IP in major worldwide markets. Our target, USP6, has demonstrated invivo efficacy with supporting human epidemiological survival data. These data support a broad cancer indication with an adult market estimated 5 year sales at $2 billion
CEO/Top Company Official
Randall N. Hyer, MD, PhD, MPH
Lead Product in Development
MER-101, an mRNA delivered novel immunostimulatory protein with human epidemiological data showing a survival benefit in numerous solid cancers.
Development Phase of Primary Product